Mutation of the retinoblastoma gene (RB1) tumour suppressor occurs in one-third of all human tumours and is particularly associated with retinoblastoma and osteosarcoma 1 . Numerous functions have been ascribed to the product of the human RB1 gene, the retinoblastoma protein (pRb). The best known is pRb's ability to promote cell-cycle exit through inhibition of the E2F transcription factors and the transcriptional repression of genes encoding cell-cycle regulators 1 . In addition, pRb has been shown in vitro to regulate several transcription factors that are master differentiation inducers 2 . Depending on the differentiation factor and cellular context, pRb can either suppress or promote their transcriptional activity. For example, pRb binds to Runx2 and potentiates its ability to promote osteogenic differentiation in vitro 3 . In contrast, pRb acts with E2F to suppress peroxisome proliferatoractivated receptor c subunit (PPAR-c), the master activator of adipogenesis 4,5 . Because osteoblasts and adipocytes can both arise from mesenchymal stem cells, these observations suggest that pRb might play a role in the choice between these two fates. However, so far, there is no evidence for this in vivo. Here we use mouse models to address this hypothesis in mesenchymal tissue development and tumorigenesis. Our data show that Rb status plays a key role in establishing fate choice between bone and brown adipose tissue in vivo.
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Mutations in RB1 (70-90% of cases) and TP53 (50-70% of cases) are strongly associated with human osteosarcoma 6, 7 . To model osteosarcoma in the mouse, we crossed Rb fl/fl (ref. 8 ) and p53 fl/fl (ref. 9) conditional mutant mice with a transgenic line, Prx1-Cre 10 , which expresses Cre recombinase in uncommitted mesenchymal cells that contribute to bone, muscle and both white and brown adipose tissue ( Supplementary Fig. 1a-c) . The homozygous deletion of Rb and/or p53 by Prx1-Cre yielded viable neonates with no detectable developmental defects (data not shown), allowing us to determine the affect of Rb and/ or p53 loss on sarcomagenesis ( Table 1 ). The Prx1-Cre;p53 fl/fl animals developed osteosarcoma (62%), rhabdomyosarcomas (15%) and/or undifferentiated sarcomas (12%). In contrast, deletion of Rb alone did not yield sarcomas. However, Rb mutation had a profound effect on the tumour spectrum of Prx1-Cre;p53 fl/fl mice ( Table 1 and Fig. 1a ): deletion of one Rb allele increased the frequency of osteosarcomas (to 92%), whereas mutation of both Rb alleles shifted the tumour spectrum away from osteosarcoma (now 18%) and towards hibernomas (91%; Supplementary Fig. 2 ). This propensity for brown-fat, as opposed to white-fat, tumours fits with previous studies showing that Rb loss promotes brown-fat over white-fat differentiation [11] [12] [13] . Genotyping confirmed that the tumour cells had undergone Cremediated recombination of Rb and/or p53 ( Fig. 1b and data not shown). Moreover, it showed that the Prx1-Cre;Rb 1/fl ;p53 fl/fl tumours consistently retained the wild-type Rb allele ( Fig. 1b and data not shown). Thus Rb acts in a dose-dependent manner to modulate the spectrum of tumours arising from p53-deficient, uncommitted mesenchymal stem cells: osteosarcomas predominant in the presence of Rb, whereas loss of Rb strongly favours hibernoma formation.
Given that Rb loss in p53 mutant uncommitted mesenchymal cells disfavours osteosarcoma formation, we also investigated the affect of Rb loss in a bone-committed progenitor. For this, we deleted Rb and/ or p53 using the Osx-Cre transgenic 14 , which uses Osterix promoter sequences to express Cre in the pre-oestoblast ( Supplementary  Fig. 1d ). In this model 15 , Osx-Cre;p53 fl/fl mice specifically develop osteosarcoma (100%) whereas Osx-Cre;Rb fl/fl ;p53 fl/fl mice develop osteosarcoma (53%), hibernomas (46%) and sarcomas (2%). We established cell lines from multiple (at least three) independent Osx-Cre;p53 fl/fl and Osx-Cre;Rb fl/fl ;p53 fl/fl osteosarcomas and discovered that the two genotypes have distinct differentiation properties ( Fig. 2 and data not shown). The Rb;p53 (DKO) osteosarcoma cell lines expressed messenger RNAs (mRNAs) that are characteristic of bone and fat differentiation ( Fig. 2a ). Indeed, their expression pattern more closely resembled that of mesenchymal stem cells than primary osteoblasts ( Supplementary Fig. 3 ). Accordingly, culture in the appropriate differentiation media induced these DKO cells to adopt either the adipogenic or osteoblastic fate ( Fig. 2a ). In contrast, the p53KO osteosarcoma cell lines closely resembled pre-osteoblasts based on their gene expression patterns, but these cells were unable to differentiate into either bone or fat ( Fig. 2a and Supplementary Fig. 3 ). Because this differentiation block occurs in the p53-null osteosarcoma cell lines, but not p53-deficient primary osteoblasts 16 , it likely reflects their transformed state. We used these p53KO osteosarcoma cells to determine whether Rb loss was sufficient to alter the differentiation potential of blocked pre-oestoblasts by introducing control (shLuc) or Rb-specific (shRb) short hairpin RNAs (shRNAs). pRb was readily detectable in shLuc-p53KO, but not shRb-p53KO, osteosarcoma cells ( Fig. 2b ). Strikingly, without addition of differentiation media, pRb knockdown downregulated the bone-specific mRNA Bsp and upregulated the fat regulator Pparc (Fig. 2b ). Accordingly, these shRb-p53KO osteosarcoma cells were now able to differentiate into either bone or fat in vitro ( Fig. 2c ). Moreover, when transplanted into nude mice, the shRb-p53KO osteosarcoma cells formed more aggressive tumours than the parental p53KO osteosarcoma cells, and these were of mixed lineage (fat, bone and undifferentiated sarcomas), in stark contrast to the undifferentiated osteoblastic tumours arising from either control shLuc-p53KO or parental p53KO osteosarcoma cell lines ( Fig. 2d , Supplementary Fig. 4 and data not shown). Thus pRb loss is sufficient to override the differentiation block of these p53-deficient tumour cell lines and expand their fate commitment to include the adipogenic state. We also examined the consequences of reintroducing Rb into the DKO osteosarcoma cells. For this, we induced pRb in confluencearrested DKO osteosarcoma cells using a doxocycline-inducible expression system (DKO-Rb Dox-ON ; Supplementary Fig. 5 ). Remarkably, pRb restoration caused the DKO osteosarcoma cells to adopt the differentiation state of the p53KO osteosarcoma cell lines within 2 days: it induced downregulation of adipogenic markers and upregulation of osteogenic markers, and the cells were unable to differentiate into fat (Supplementary Fig. 5 ). Thus removal or reintroduction of Rb appears sufficient to switch lineage specification between osteoblastic commitment and multipotency.
In vitro studies have shown that pRb can act with E2F to enforce transcriptional repression of Pparc 4,5 , and bind, and potentiate the transcriptional activity of, the osteogenic regulator RUNX2 (ref. 3 ). We hypothesized that pRb's role in these processes might underlie the Rb knockdown was confirmed by immunoprecipitation and qPCR showed that this caused downregulation of bone markers Bsp (also Coll1a and Alp, data not shown), and upregulation of fat markers Pparc (also Ap2 and C/ebpa, data not shown) without culture in differentiating media. Bars represent the mean of three independent experiments (6 SD). c, The osteogenic and adipogenic potential of shLuc-and shRb-p53KO cell lines was assessed 0, 7, 14 and 21 days after differentiation induction by Alizarin red and Oil red O staining. A representative time point (14 days) is shown. d, Haematoxylin and eosin staining of representative tumours derived from shLuc-and shRb-p53KO cell lines injected subcutaneously into immunocompromised mice. shRb-p53KO osteosarcoma cells consistently (ten out of ten injections) yielded tumours that arose faster, and were more aggressive, than those arising from the parental p53KO osteosarcoma controls (ten injections). Moreover, the shRb-p53KO osteosarcoma-derived tumours were frequently (six out of ten injections) mixed lineage (top inset shows fat neoplasm; bottom inset shows bone/undifferentiated sarcoma), whereas the control shLuc-p53KO tumours were uniformly (ten out of ten injections) osteosarcomas. Additional analysis of these tumours (haematoxylin and eosin, Sirius red staining and Runx2 immunohistochemistry) is shown in Supplementary Fig. 4 . NATURE | Vol 466 | 26 August 2010 LETTERS effect of Rb on adipogenesis versus osteogenesis. Thus we used our DKO-Rb Dox-ON cells to determine whether the presence or absence of pRb modulated these transcriptional regulators (Fig. 3) . First, we used chromatin-immunoprecipitation assays to investigate promoter regulation of Pparc and representative Runx2-responsive genes Coll1a (Fig. 3a ) and osteocalcin (Oc; data not shown). pRb-induction caused both pRb and E2f4, the predominant repressive E2F, to be recruited to the Pparc promoter ( Fig. 3a ) and this correlated with Pparc mRNA downregulation (Fig. 3a) . Contemporaneously, pRb bound to Coll1a and Oc and this was accompanied by increased promoter occupancy of Runx2 and upregulation of Coll1a and Oc mRNAs ( Fig. 3a and data not shown) . Importantly, these changes in Pparc, Coll1a and Oc regulation were all detected within 2 days of pRb induction and without addition of differentiation-inducing media. In addition, we found that Runx2 associated with pRb in the p53KO, but not the DKO, osteosarcoma cells, and that its transcriptional activity was eightfold higher in the former population than the latter (Fig. 3b ). Thus the presence or absence of pRb directly modulates the levels and activity of Pparc and Runx2 in accordance with the preferential commitment of our osteosarcoma cell lines to the osteogenic versus the adipogenic lineage.
The preceding experiments establish a clear role for pRb in fate commitment bias in vivo and in vitro. However, because this analysis was conducted in p53-deficient cells, it is unclear whether Rb alone is sufficient to determine this plasticity or whether transformation is also required. To address this, we isolated primary osteoblasts from the calvaria of Rb fl/fl , p53 fl/fl or Rb fl/fl ;p53 fl/fl at embryonic day 18.5. We brought these cells to confluence, to minimize the influence of altered proliferation, infected them with adenoviruses expressing Cre or a green fluorescent protein (GFP) control and then assayed differentiation. As expected, the control-infected osteoblasts were able to undergo osteogenesis but not adipogenesis ( Fig. 4a and data not shown). Similarly, p53 loss had no effect on this fate commitment 16 (Fig. 4a) . In stark contrast, deletion of Rb, either alone or with p53, allowed these cells to adopt either the bone or fat lineage ( Fig. 4a and data not shown). This switch to multipotency correlated with the significant upregulation of adipogenic markers before the induction of differentiation (Fig. 4b) . Thus pRb-loss is sufficient to alter the fate commitment in otherwise wild-type calvarial osteoblasts.
In vitro culture can modulate the plasticity of cells. Thus we examined the role of Rb in fate choice in vivo. For this, we used a third transgenic strain, Meox2-Cre, which expresses Cre in the embryo proper from embryonic day 6.5 (ref. 17 ). Meox2-Cre;Rb fl/fl embryos survived to birth 18 . We isolated wild-type (Meox2-Cre;Rb 1/1 ) and Rb mutant (Meox2-Cre;Rb fl/fl ) littermates at embryonic days 15.5 and 18.5 and examined both bone and brown-fat development. First, there was a significant reduction in the level of calcified bone matrix in both the calvaria and long bones of Rb mutant compared with wild-type embryos 19 (Fig. 4c ). Moreover, quantitative PCR (qPCR) established that Runx2 mRNA was present at appropriate levels in the Rb mutant calvarial osteoblasts at embryonic day 18.5, but there was a downregulation of other bone markers and a clear upregulation of fat-associated mRNAs (Fig. 4c) . In parallel, we found that the level of brown fat dramatically increased in the Rb mutant compared with the wild-type controls at embryonic day 18.5 ( Fig. 4d and Supplementary Fig. 6 ). Thus Rb loss in an, otherwise wild-type, embryo impairs bone differentiation and expands the fat compartment.
Our data establish a clear role for pRb in determining the fate choice of mesenchymal progenitors and the lineage commitment of preosteoblasts. This occurs both in vitro and in vivo, irrespective of whether these cells are transformed or otherwise wild type. In vivo, Rb loss favours adipogenesis over osteogenesis to the extent that it can reduce the levels of calcified bone and greatly increase the levels of brown fat. Moreover, Rb loss in pre-osteoblasts is sufficient to disfavour commitment to the osteogenic state and restore multipotency. It is possible that Rb loss allows expansion of a rare multipotent progenitor population that exists within the pre-osteoblast compartment. Alternatively, Rb loss could be actively reprogramming the preosteoblasts by driving either trans-differentiation to the adipogenic lineage or true de-differentiation to the multipotent progenitor stage. Between the two reprogramming models we favour de-differentiation, based on both the expression of multi-lineage differentiation markers in the DKO osteosarcoma cells ( Supplementary Fig. 3 ) and the broadening of the tumour spectrum from solely oesteosarcomas in the Osx-Cre;p53 fl/fl animals to include not only osteosarcomas and hibernomas but also sarcomas in the Osx-Cre;Rb fl/fl ;p53 fl/fl mice. Finally, our data offer potential insight into the cell of origin for osteosarcomas. Specifically, given the high frequency of RB1 mutations in human osteosarcoma, we were surprised to find that Rb mutation predisposes mesenchymal cells away from the osteoblastic state. Given this finding, we speculate that RB1 mutant osteosarcomas are likely to arise from more committed osteoblastic lineages than from uncommitted mesenchymal progenitors. In this setting, RB1 loss could enable dedifferentiation and thereby synergize with other mutations to promote tumorigenesis.
METHODS SUMMARY
Animal maintenance and histological analyses. Osteoblast cell lines and primary osteoblasts were generated and analysed as described in Methods or previously 19 . Knockdown of Rb in the p53KO osteosarcoma cells was achieved using the pMLP-miR30-based short hairpin. Rb targeted sequence: CACGGACGTGTGAACTTATATA, Luc control: GAGCTC CCGTGAATTGGAATCC. Adenoviruses expressing Cre or GFP were provided by the University of Iowa Gene Transfer Vector Core. For immunoprecipitations and immunoblotting, proteins were extracted with a Triton X-100-based buffer and quantified by the BCA Protein Assay Reagent (Pierce). Antibodies were from Santa Cruz Biotechnology (pRb (H-153), E2F1 (C-20) and E2F4 (C-20)), BD Pharmingen (pRb), Ambion (GAPDH) and MBL (Runx2). Dual luciferase assays were performed as described by the manufacturer (Promega). The Runx2 reporter p6OSE2-Luc and control p4Luc were provided by G. Karsenty.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
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